A pilot, open study on the treatment of refractory schizophrenia with risperidone and clozapine

R. Cavallaro, C. Colombo, E. Smeraldi

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The aim of this report is to show the results of a pilot, open label treatment programme for resistant schizophrenia in which risperidone was used before clozapine. Thirteen DSM III R, drug resistant schizophrenics were treated with risperidone p.o. at doses up to 16 mg/day for three months. Clinical assessment was performed before and after 1, 2 and 3 months of treatment by means of the Brief Psychiatric Rating Scale (BPRS) and of the Scales for the Assessment of Positive and Negative Symptoms of Schizophrenia. Non-responders to risperidone were then treated with clozapine (up to 600 mg/day) for the next month. Seven patients responded to risperidone (improvement over 20 per cent in each rating scale, BPRS total score below 35), while five risperidone non-responders or partial responders improved dramatically after following clozapine treatment. Results suggest that heterogeneity in response to atypical antipsychotics may overshadow a heterogeneity in underlying biological factors.

Original languageEnglish
Pages (from-to)231-234
Number of pages4
JournalHuman Psychopharmacology
Volume10
Issue number3
DOIs
Publication statusPublished - 1995

Fingerprint

Risperidone
Clozapine
Schizophrenia
Brief Psychiatric Rating Scale
Therapeutics
Biological Factors
Diagnostic and Statistical Manual of Mental Disorders
Antipsychotic Agents
Pharmaceutical Preparations

Keywords

  • Drug resistant
  • Schizophrenia
  • Treatment

ASJC Scopus subject areas

  • Clinical Neurology
  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Neuroscience(all)
  • Neurology
  • Pharmacology
  • Psychology(all)

Cite this

A pilot, open study on the treatment of refractory schizophrenia with risperidone and clozapine. / Cavallaro, R.; Colombo, C.; Smeraldi, E.

In: Human Psychopharmacology, Vol. 10, No. 3, 1995, p. 231-234.

Research output: Contribution to journalArticle

@article{ede131fb38604b49889348fd1a592169,
title = "A pilot, open study on the treatment of refractory schizophrenia with risperidone and clozapine",
abstract = "The aim of this report is to show the results of a pilot, open label treatment programme for resistant schizophrenia in which risperidone was used before clozapine. Thirteen DSM III R, drug resistant schizophrenics were treated with risperidone p.o. at doses up to 16 mg/day for three months. Clinical assessment was performed before and after 1, 2 and 3 months of treatment by means of the Brief Psychiatric Rating Scale (BPRS) and of the Scales for the Assessment of Positive and Negative Symptoms of Schizophrenia. Non-responders to risperidone were then treated with clozapine (up to 600 mg/day) for the next month. Seven patients responded to risperidone (improvement over 20 per cent in each rating scale, BPRS total score below 35), while five risperidone non-responders or partial responders improved dramatically after following clozapine treatment. Results suggest that heterogeneity in response to atypical antipsychotics may overshadow a heterogeneity in underlying biological factors.",
keywords = "Drug resistant, Schizophrenia, Treatment",
author = "R. Cavallaro and C. Colombo and E. Smeraldi",
year = "1995",
doi = "10.1002/hup.470100310",
language = "English",
volume = "10",
pages = "231--234",
journal = "Human Psychopharmacology",
issn = "0885-6222",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - A pilot, open study on the treatment of refractory schizophrenia with risperidone and clozapine

AU - Cavallaro, R.

AU - Colombo, C.

AU - Smeraldi, E.

PY - 1995

Y1 - 1995

N2 - The aim of this report is to show the results of a pilot, open label treatment programme for resistant schizophrenia in which risperidone was used before clozapine. Thirteen DSM III R, drug resistant schizophrenics were treated with risperidone p.o. at doses up to 16 mg/day for three months. Clinical assessment was performed before and after 1, 2 and 3 months of treatment by means of the Brief Psychiatric Rating Scale (BPRS) and of the Scales for the Assessment of Positive and Negative Symptoms of Schizophrenia. Non-responders to risperidone were then treated with clozapine (up to 600 mg/day) for the next month. Seven patients responded to risperidone (improvement over 20 per cent in each rating scale, BPRS total score below 35), while five risperidone non-responders or partial responders improved dramatically after following clozapine treatment. Results suggest that heterogeneity in response to atypical antipsychotics may overshadow a heterogeneity in underlying biological factors.

AB - The aim of this report is to show the results of a pilot, open label treatment programme for resistant schizophrenia in which risperidone was used before clozapine. Thirteen DSM III R, drug resistant schizophrenics were treated with risperidone p.o. at doses up to 16 mg/day for three months. Clinical assessment was performed before and after 1, 2 and 3 months of treatment by means of the Brief Psychiatric Rating Scale (BPRS) and of the Scales for the Assessment of Positive and Negative Symptoms of Schizophrenia. Non-responders to risperidone were then treated with clozapine (up to 600 mg/day) for the next month. Seven patients responded to risperidone (improvement over 20 per cent in each rating scale, BPRS total score below 35), while five risperidone non-responders or partial responders improved dramatically after following clozapine treatment. Results suggest that heterogeneity in response to atypical antipsychotics may overshadow a heterogeneity in underlying biological factors.

KW - Drug resistant

KW - Schizophrenia

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0029012831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029012831&partnerID=8YFLogxK

U2 - 10.1002/hup.470100310

DO - 10.1002/hup.470100310

M3 - Article

VL - 10

SP - 231

EP - 234

JO - Human Psychopharmacology

JF - Human Psychopharmacology

SN - 0885-6222

IS - 3

ER -